Metabolites of cerebellar neurons and hippocampal neurons play opposite roles in pathogenesis of Alzheimer's disease

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Du, Jing ^a   Sun, Bing ^a   Chen, Kui ^b   Zhang, Lang ^a   Liu, Shubo ^a   Gu, Qingquan ^a   Fan, Li ^b,c   Zhao, Nanming ^a   Wang, Zhao ^a  

^a Tsinghua University   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c Albert Starr Academic Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA ACTIN; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALANCE IMPAIRMENT; BRAIN CELL; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; ENZYME DEGRADATION; HIPPOCAMPUS; LEARNING; MAZE TEST; MEMORY; METABOLITE; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; ANIMAL; CEREBELLUM; DISEASE MODEL; GENETICS; METABOLISM; NERVE CELL;

MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BIOLOGICAL MARKERS; CEREBELLUM; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MICE; MICE, TRANSGENIC; NEURONS;

EID: 65849162974     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005530     Document Type: Article

References (35)

1. Snider WD (1994) Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. Cell 77: 627-638.
2. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
3. Hempstead BL (2006) Dissecting the diverse actions of pro- and mature neurotrophins. Curr Alzheimer Res 3: 19-24.
4. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, et al. (1997) Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 278: 1363-1371.
5. Citron M (2002) Alzheimer's disease: treatments in discovery and development. Nat Neurosci 5 Suppl: 1055-1057.
6. Greene JD, Baddeley AD, Hodges JR (1996) Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Neuropsychologia 34: 537-551.
7. Pillon B, Deweer B, Agid Y, Dubois B (1993) Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol 50: 374-379.
8. Hardy J, Gwinn-Hardy K (1998) Genetic classification of primary neurodegenerative disease. Science 282: 1075-1079.
9. Giannakopoulos P, Hof PR, Michel JP, Guimon J, Bouras C (1997) Cerebral cortex pathology in aging and Alzheimer's disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts. Brain Res Brain Res Rev 25: 217-245.
10. West MJ, Coleman PD, Flood DG, Troncoso JC (1994) Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344: 769-772.
11. Bobinski M, de Leon MJ, Tarnawski M, Wegiel J, Reisberg B, et al. (1998) Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Brain Res 805: 267-269.
12. Li YT, Woodruff-Pak DS, Trojanowski JQ (1994) Amyloid plaques in cerebellar cortex and the integrity of Purkinje cell dendrites. Neurobiol Aging 15: 1-9.
13. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
14. Kim HJ, Chae SC, Lee DK, Chromy B, Lee SC, et al. (2003) Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. Faseb J 17: 118-120.
15. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 26: 645-654.
16. Selkoe DJ (1993) Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci 16: 403-409.
17. Saido TC (1998) Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol Aging 19: S69-75.
18. Cummings JL (2004) Alzheimer's disease. N Engl J Med 351: 56-67.
19. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, et al. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106: 1489-1499.
20. Zlokovic BV (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89: 807-811.
21. Selkoe DJ (2001) Clearing the brain's amyloid cobwebs. Neuron 32: 177-180.
22. Qu HY, Zhang T, Li XL, Zhou JP, Zhao BQ, et al. (2008) Transducible P11-CNTF rescues the learning and memory impairments induced by amyloid-beta peptide in mice. Eur J Pharmacol 594: 93-100.
23. Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H (2008) IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. J Immunol 181: 6503-6513.
24. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, et al. (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 24: 11120-11126.
25. Miyan JA, Nabiyouni M, Zendah M (2003) Development of the brain: a vital role for cerebrospinal fluid. Can J Physiol Pharmacol 81: 317-328.
26. Du J, Yang X, Zhang L, Zeng Y (2009) Expression of TRPM8 in the distal cerebrospinal fluid-contacting neurons in the brain mesencephalon of rats. Cerebrospinal Fluid Res 6: 3.
27. Smith QR, Woodbury DM, Johanson CE (1981) Uptake of 36Cl and 22Na by the choroid plexus-cerebrospinal fluid system: evidence for active chloride transport by the choroidal epithelium. J Neurochem 37: 107-116.
28. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, et al. (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 4: 887-893.
29. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, et al. (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6: 143-150.
30. Chen G, Chen KS, Knox J, Inglis J, Bernard A, et al. (2000) A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408: 975-979.
31. Janus C, D'Amelio S, Amitay O, Chishti MA, Strome R, et al. (2000) Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes. Neurobiol Aging 21: 541-549.
32. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982.
33. Venable N, Kelly PH (1990) Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice. Psychopharmacology (Berl) 100: 215-221.
34. Kelly PH, Bondolfi L, Hunziker D, Schlecht HP, Carver K, et al. (2003) Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging 24: 365-378.
35. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754.